Literature DB >> 19333790

Evaluation of CD44 and CD44v6 in colorectal carcinoma patients: soluble forms in relation to tumor tissue expression and metastasis.

Zahra Amirghofran1, Seyed Amir Jalali, Seyed Vahid Hosseini, Mohammad Vasei, Behnam Sabayan, Abbas Ghaderi.   

Abstract

INTRODUCTION: It has been shown that CD44 may be associated with poor prognosis in various human malignancies. This study was designed to investigate and compare the prognostic relevance and clinical value of soluble forms of CD44 and its variant v6 (CD44v6) and their tissue expression in colorectal carcinoma.
MATERIALS AND METHODS: Serum levels of pre- and postoperative CD44 and CD44v6 molecules were evaluated in 37 colorectal cancer patients and compared to healthy individuals. RESULTS AND DISCUSSION: The serum levels of soluble CD44 and CD44v6 showed no significant decrease after surgical resection of the tumor (p = 0.5). Both CD44 and CD44v6 serum levels either before or after surgery were significantly higher in patients than in normal individuals (p < 0.001). The serum level of CD44v6 molecule was higher in patients with lymph node metastasis than other patients (p = 0.05) implying the role of this molecule in tumor progression. Immunohistochemical staining showed expression of CD44 in 14.3% and CD44v6 in 42.9% of the tumor samples. The expression of CD44v6 was associated with metastatic involvement of lymph nodes (p = 0.03). CD44v6 expression was positively correlated with its level in the serum of patients (p = 0.04).
CONCLUSIONS: Results of this study showed that CD44v6 expression level either in the soluble form or in the cell membrane is associated with tumor metastasis indicating the importance of this molecule in progression of colorectal carcinoma. The serum levels of soluble CD44 as well as CD44v6 might be useful markers for tumor screening.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19333790     DOI: 10.1007/s12029-009-9062-2

Source DB:  PubMed          Journal:  J Gastrointest Cancer


  27 in total

1.  Soluble CD44 variants in the serum of patients with urological malignancies.

Authors:  M Lein; K Jung; S Weiss; D Schnorr; S A Loening
Journal:  Oncology       Date:  1997 May-Jun       Impact factor: 2.935

2.  Comparison of CD44 expression in primary tumours and metastases of colorectal cancer.

Authors:  R Bendardaf; A Algars; A Elzagheid; E Korkeila; R Ristamäki; H Lamlum; Y Collan; K Syrjänen; S Pyrhönen
Journal:  Oncol Rep       Date:  2006-10       Impact factor: 3.906

3.  Soluble CD44 and CD44v6 serum levels in patients with colorectal cancer are independent of tumor stage and tissue expression of CD44v6.

Authors:  S Weg-Remers; U Hildebrandt; G Feifel; C Moser; M Zeitz; A Stallmach
Journal:  Am J Gastroenterol       Date:  1998-05       Impact factor: 10.864

4.  Epidemiological changes in colorectal cancer in Shiraz, Iran: 1980-2000.

Authors:  Seyed Vahid Hosseini; Ahmad Izadpanah; Hooman Yarmohammadi
Journal:  ANZ J Surg       Date:  2004-07       Impact factor: 1.872

5.  Predictive factors of years of potential life lost by colorectal cancer.

Authors:  Julian Perez-Palma; Joaquin Marchena-Gomez; Mercedes Dorta-Espineira; Nieves Lorenzo-Rocha; Alberto Bravo-Gutierrez; Vicente Medina-Arana
Journal:  Eur J Gastroenterol Hepatol       Date:  2008-08       Impact factor: 2.566

6.  Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons.

Authors:  G R Screaton; M V Bell; D G Jackson; F B Cornelis; U Gerth; J I Bell
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

7.  Levels of v5 and v6 CD44 splice variants in serum of patients with colorectal cancer are not correlated with pT stage, histopathological grade of malignancy and clinical features.

Authors:  Bogdan Zalewski
Journal:  World J Gastroenterol       Date:  2004-02-15       Impact factor: 5.742

8.  Serum CD44 splice variants in cervical cancer patients.

Authors:  C Kainz; C Tempfer; S Winkler; G Sliutz; H Koelbl; A Reinthaller
Journal:  Cancer Lett       Date:  1995-04-14       Impact factor: 8.679

9.  New CD44 splice variants associated with human breast cancers.

Authors:  N Iida; L Y Bourguignon
Journal:  J Cell Physiol       Date:  1995-01       Impact factor: 6.384

Review 10.  Lymphocyte adhesion to endothelium.

Authors:  U Dianzani; F Malavasi
Journal:  Crit Rev Immunol       Date:  1995       Impact factor: 2.214

View more
  9 in total

1.  CD44v6 expression in patients with stage II or stage III sporadic colorectal cancer is superior to CD44 expression for predicting progression.

Authors:  L H Zhao; Q L Lin; J Wei; Y L Huai; K J Wang; H Y Yan
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

2.  Comprehensive Analysis of Ferroptosis- and Immune-Related Signatures to Improve the Prognosis and Diagnosis of Kidney Renal Clear Cell Carcinoma.

Authors:  Xiao-Liang Xing; Yan Liu; Jiheng Liu; Huanfa Zhou; Huirong Zhang; Qi Zuo; Ping Bu; Tong Duan; Yan Zhou; Zhiquan Xiao
Journal:  Front Immunol       Date:  2022-05-10       Impact factor: 8.786

3.  CD44 splice variant (CD44v3) promotes progression of urothelial carcinoma of bladder through Akt/ERK/STAT3 pathways: novel therapeutic approach.

Authors:  Vivek Anand; Madhuram Khandelwal; Sandeep Appunni; Nidhi Gupta; Amlesh Seth; Prabhjot Singh; Sandeep Mathur; Alpana Sharma
Journal:  J Cancer Res Clin Oncol       Date:  2019-09-16       Impact factor: 4.553

4.  CD44v6 down-regulation is an independent prognostic factor for poor outcome of colorectal carcinoma.

Authors:  Lili Wang; Qin Liu; Dongliang Lin; Maode Lai
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

5.  Pilot study: alteration of deleted in liver cancer1 and phosphorylated focal adhesion kinase Y397 cytoplasmic expression and the prognostic value in advanced epithelial ovarian carcinoma.

Authors:  Dong-Mei Fan; Hui-Rong Shi
Journal:  Int J Mol Sci       Date:  2011-11-29       Impact factor: 5.923

6.  Hyaluronic acid-coated chitosan nanoparticles induce ROS-mediated tumor cell apoptosis and enhance antitumor efficiency by targeted drug delivery via CD44.

Authors:  Tao Wang; Jiahui Hou; Chang Su; Liang Zhao; Yijie Shi
Journal:  J Nanobiotechnology       Date:  2017-01-10       Impact factor: 10.435

7.  Correlation analysis of expression and prognosis of TTF-1 and CD44v6 in undifferentiated lung carcinoma.

Authors:  Yudong Wu; Xia Yu; Mingzhu Liang; Baojun Wang
Journal:  Oncol Lett       Date:  2019-07-30       Impact factor: 2.967

8.  Gene expression and DNA methylation analyses suggest that two immune related genes are prognostic factors of colorectal cancer.

Authors:  Xiao-Liang Xing; Zhi-Yong Yao; Chaoqun Xing; Zhi Huang; Jing Peng; Yuan-Wu Liu
Journal:  BMC Med Genomics       Date:  2021-04-28       Impact factor: 3.063

9.  Effects of different sequences of pulmonary artery and vein ligations during pulmonary lobectomy on blood micrometastasis of non-small cell lung cancer.

Authors:  Ping-Ping Song; Weidi Zhang; Baijiang Zhang; Qi Liu; Jiajun DU
Journal:  Oncol Lett       Date:  2012-11-09       Impact factor: 2.967

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.